The US FDA has issued a Talk Paper advising of changes to the US Strattera [atomoxetine] labelling

Author：  

Publisher： Adis International

ISSN： 0114-9954

Source： Reactions Weekly, Vol.1, Iss.1033, 2005-01, pp. : 2-2

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Jones Pharma Incorporated has issued a `Dear Healthcare Professional' letter advising of changes to the US labelling of Levoxyl [levothyroxine sodium].

By  

Reactions Weekly, Vol. 1, Iss. 1023, 2004-01 ,pp. : 2-2

Adis International

Access to resources Recommend Favorite

The US FDA has issued a statement on the use of conjugated estrogens/medroxyprogesterone

By  

Inpharma, Vol. 1, Iss. 1359, 2002-01 ,pp. : 5-5

Adis International

Access to resources Recommend Favorite

Amgen Inc. has issued a `Dear Health Care Professional' letter advising of important changes to the labelling for Aranesp

By  

Reactions Weekly, Vol. 1, Iss. 1035, 2005-01 ,pp. : 2-2

Adis International

Access to resources Recommend Favorite

The US FDA has approved acetadote [acetylcysteine] labelling updates

By  

Reactions Weekly, Vol. 1, Iss. 1093, 2006-01 ,pp. : 3-3

Adis International

Access to resources Recommend Favorite

Tiratricol warning issued by US FDA

By  

Inpharma, Vol. 1, Iss. 1266, 2000-01 ,pp. : 22-22

Adis International

Access to resources Recommend Favorite